Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01715233 | Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. | completed | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT02812641 | Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC | unknown | Phase 2 | 50 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 |
| NCT03857763 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 0 | Feb 28, 2019 | clinicaltrials |
| NCT01831531 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | completed | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03833466 | Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)(ECMTPneo) | unknown | Phase 2 | 15 | Peking UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02353936 | A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT01372202 | CHFR Methylation Status Esophageal Cancer Study(J10130) | terminated | Phase 2 | 31 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03817658 | A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC | unknown | Phase 2 | 725 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03811379 | Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy | unknown | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03234842 | Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer(ES01) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT00493025 | Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery | terminated | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03292757 | FLOTOR Pilot Study(FLOTOR) | completed | Phase 1 / Phase 2 | 21 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01446874 | Prevention of Post-operative Pneumonia (POPP)(POPP) | terminated | Phase 2 / Phase 3 | 150 | Washington University School of MedicineOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT03732508 | SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | unknown | Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00215644 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer(MATRIX EG) | completed | Phase 2 | 72 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Nov 2, 2018 | clinicaltrials |
| NCT00137813 | Avastin and Taxotere for Esophagogastric Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT03223662 | Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2018 | clinicaltrials |
| NCT00531180 | 4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT02234180 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery | terminated | Phase 2 | 3 | Academic and Community Cancer Research UnitedOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03706326 | CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00096031 | S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | completed | Phase 2 | 63 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 26, 2018 | clinicaltrials |
| NCT03649945 | Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer | unknown | Phase 2 | 186 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 28, 2018 | clinicaltrials |
| NCT00607594 | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Aug 23, 2018 | clinicaltrials |
| NCT01608464 | Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer | terminated | Phase 2 | 170 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00891878 | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 12 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00711412 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer | completed | Phase 2 | 44 | Northwestern UniversityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03585673 | Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma(DOSE) | unknown | Phase 2 | 38 | Sung Yong OhOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT01746043 | A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT00316862 | Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery | completed | Phase 2 | 82 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 8, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT00938470 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT02924909 | Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer(QUIMERA) | unknown | Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Mar 20, 2018 | clinicaltrials |
| NCT00827671 | Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma(TRACC) | terminated | Phase 2 | 12 | P.O. WitteveenOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02392377 | Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00256269 | Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma | terminated | Phase 2 | 4 | University of California, IrvineOTHER | 1 | Jan 26, 2018 | clinicaltrials |
| NCT00848783 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | terminated | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT03126708 | Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 150 | Peking UniversityOTHER | 1 | Jan 4, 2018 | clinicaltrials |
| NCT01097304 | Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00201747 | Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer | completed | Phase 2 | 80 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02545751 | SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer | unknown | Phase 2 | 29 | Hangzhou Cancer HospitalOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00137852 | Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer | completed | Phase 2 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02384811 | Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00394433 | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT03224221 | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | unknown | Phase 2 | 189 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT02959385 | A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 18, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2019source: clinicaltrials